China consults on measures for monitoring adverse reactions from cosmetics

摘要

The National Medical Products Administration (NMPA) has published draft measures which, if approved, would require cosmetics companies to establish a system for adverse reaction monitoring. This would apply to all companies that have submitted registrations or filed/notified for cosmetic products in China.